Top 50 Ai For Drug Discovery in Asia

Standigm utilizes artificial intelligence to enhance drug discovery through first-in-class target identification and lead optimization, significantly reducing the average material optimization time from 4.5 years to 1.5 years. The platform provides end-to-end solutions that improve the efficiency and success rates of new drug development processes.

Protai utilizes machine learning and mass spectrometry-derived proteomics data to create a vertically integrated platform for drug discovery. This technology enables precise targeting of complex disease drivers, facilitating the identification of novel therapeutic targets and improving the development of effective treatments.

TandemAI provides a physics-based and AI-driven platform that integrates computational analyses with wet lab experimentation to enhance drug discovery workflows. By offering a collaborative workspace and advanced algorithms, TandemAI enables research teams to accelerate the development of new therapeutics more efficiently than traditional methods.

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

Perpetual Medicines develops a computational peptide drug discovery engine that utilizes advanced computational physics and AI technologies to explore untapped peptide chemical space. The platform targets previously undruggable biological targets, enhancing the efficiency and quality of peptide drug candidates.

Unnatural Products utilizes an AI-enhanced discovery platform to engineer synthetic macrocycles that mimic natural macrocycles, enabling targeted therapies for complex drug targets that are typically undruggable by small molecules or biologics. This approach addresses the limitations of existing drug modalities by providing a new class of therapeutics with improved cell permeability and oral bioavailability.

Engine Biosciences utilizes machine learning and high-throughput biology to identify genetic interactions within complex disease networks, enabling the development of targeted therapeutics and biomarkers for specific patient populations. This approach significantly accelerates the research and development process for new medical therapies, reducing costs and improving clinical outcomes for a range of solid tumors.

This biotechnology company utilizes artificial intelligence to cultivate and evolve proteins essential for bio-products, enhancing the efficiency of medical research. By providing reliable and rapid access to these proteins, the company addresses the need for improved medical services in the healthcare sector.

CytoReason develops a cell-centered computational model that analyzes biological data to map disease mechanisms and treatment effects. This technology enables pharmaceutical companies to prioritize drug development and make data-driven decisions by providing insights into drug performance across diverse patient populations.

QuantHealth offers an AI-driven platform that simulates patient responses to therapies, optimizing drug development. By integrating multi-modal data, the platform provides predictive insights for clinical trial design, asset valuation, and portfolio management.

Utilizes generative AI to design de novo genes and proteins that integrate multiple biological functions into compact therapeutic molecules. This approach addresses unmet medical needs by enabling the development of highly effective treatments with improved efficiency and specificity.

KYAN Therapeutics utilizes its Optim.AI™ ex vivo analytic platform to perform functional precision medicine tests that evaluate drug response using patient-derived cancer cells. This approach addresses the limitations of standard therapies by providing personalized treatment regimens based on the unique sensitivities of each patient's cancer, thereby improving treatment efficacy.

Starget Pharma develops Smart Targeted Radioligands (STRs) using proprietary peptide backbone dynamics technology to deliver targeted radiation directly to tumoral and metastatic cancer cells, minimizing damage to healthy tissues. This approach addresses the need for effective treatment options in advanced metastatic cancers, offering a broader therapeutic window compared to traditional radiation therapies.

Eleven Therapeutics utilizes synthetic chemistry and AI algorithms to develop RNA therapeutics that optimize safety, efficiency, and duration of effect. Their platform maps the vast chemical space of RNA molecules, addressing the need for precise and effective therapeutic solutions in the rapidly evolving field of RNA-based medicine.

Great Bay Bio develops biopharmaceuticals using its AI-enabled platforms, AlfaCell and AlfaMedX, which streamline cell line development and optimize cell culture media. This technology reduces the time and complexity of producing high-yield, stable cell lines, addressing inefficiencies in traditional biologics development.

Apeiron Therapeutics develops biomarker-driven small molecule therapies for cancer using structure-based, AI-driven drug design. The company focuses on creating targeted treatments for solid tumors with specific genetic deletions, addressing significant gaps in current cancer therapies.

Provides an AI-powered platform, MoleculeGEN, for de novo drug design and antibody generation, leveraging deep learning and biophysics to create novel small molecules and antibodies tailored to specific disease targets. This approach addresses the challenges of traditional drug discovery by automating hit generation, lead optimization, and toxicity prediction, enabling faster development of treatments for diseases with high unmet medical needs.

Laekna Therapeutics specializes in drug discovery and development using high-throughput screening and structure-based design to identify novel therapeutic compounds. The company focuses on addressing unmet medical needs by developing targeted treatments for complex diseases.

HITS develops AI-driven digital solutions for drug discovery, utilizing advanced molecular design and predictive modeling to enhance the efficiency of early-stage drug development. The platform addresses the challenges of traditional drug discovery by providing accurate predictions for drug-protein interactions and optimizing molecular properties, significantly reducing time and costs associated with the development process.

AION Labs is a venture studio that utilizes AI and computational technologies to enhance drug discovery and development processes by integrating extensive pharma data and real-time validation against industry standards. The company addresses inefficiencies in drug development by providing funding, expert collaboration, and structured support for scientists and tech founders tackling specific biopharma challenges.

Chemical.AI utilizes proprietary retrosynthesis algorithms and robotic lab automation to enhance chemical synthesis processes for pharmaceutical and chemical research. By integrating comprehensive chemical data, the platform improves productivity and reduces trial-and-error in drug discovery, enabling faster and more efficient development of new compounds.

Cyrus Therapeutics develops small molecule drugs targeting previously undruggable proteins to treat chronic diseases. By utilizing advanced drug discovery techniques, the company aims to create effective therapies that address significant unmet medical needs.

Panacea-ml develops a machine learning-based software system that utilizes predictive analytics to enhance patient selection and trial design for clinical studies in diseases such as ALS, diabetes, and cancer. The platform reduces trial duration and costs while increasing the likelihood of successful market approval for new treatments.

The startup develops an AI bioinformatics platform that utilizes big data analytics and predictive modeling to streamline the identification and validation of drug targets. By simplifying complex biomedical data networks, the platform enables biochemists to gain actionable insights for target identification and drug repurposing.

Sravathi AI Technology Pvt Ltd utilizes proprietary AI algorithms and molecular modeling to design and develop drug molecules, polymers, and catalysts, enhancing the efficiency of chemical synthesis and in-vitro screening. The company addresses the challenge of predicting chemical reactions and optimizing yields at atomic and electronic levels, facilitating faster drug discovery and development processes.

The startup has developed an AI-powered drug discovery platform that utilizes data-driven methodologies to enhance traditional drug design processes. By providing scientists in the pharmaceutical industry with user-friendly AI tools, the platform accelerates research timelines and facilitates the development of novel therapeutics, ultimately aiming to reduce the burden of diseases on patients.

The startup offers an online analytical platform that utilizes artificial intelligence to provide standardized data and intelligence services related to pharmaceutical drugs, patents, and companies. By delivering customized reports, the platform helps organizations minimize investment risks and enhance compliance with pharmaceutical data regulations.

NetTargets utilizes AI-enhanced systems biology and mathematical modeling to provide interpretable predictions for drug discovery, significantly reducing the risk of clinical trial failures. By simulating causal biological networks, the company helps identify effective treatment strategies and optimize patient selection, addressing the high failure rates in drug development.

ProPhet utilizes AI and machine learning to predict protein dynamics and interactions with drug candidates, enabling the identification of small molecules for hard-to-target proteins. This approach addresses the challenge of discovering therapeutics for diseases previously deemed undruggable, enhancing the efficiency and accuracy of early-stage drug discovery.

Dr. Noah Biotech utilizes an AI-driven platform to develop drug combinations specifically targeting orphan diseases, leveraging extensive bio-pharmacological data to identify effective therapeutic options. The company addresses the high failure rates in clinical trials by enhancing drug efficacy and safety through synergistic combinations, ultimately improving treatment outcomes for patients with limited therapeutic options.

The startup develops protein degradation drugs using an AI-enabled platform to identify and target disease-related proteins in cancer, neurodegenerative, and aging-related diseases. This approach provides researchers and pharmaceutical companies with a new class of therapeutics that can overcome drug resistance in life-threatening conditions.

The startup has developed a biotechnology platform that utilizes cryo-electron microscopy for structural analysis in drug discovery, enabling researchers to observe in-vivo structures without staining. This technology facilitates the identification and analysis of potential life-saving drugs by providing high-resolution insights into molecular structures.

The startup develops anticancer drugs by utilizing predictive biomarkers and a structured research approach that includes target discovery, drug discovery, medicinal chemistry, and CMC processes. This enables healthcare providers to offer more effective treatments for cancer patients, ultimately improving patient outcomes and quality of life.

Degron Therapeutics is developing a platform for the discovery of small molecule molecular glue degraders (MGDs) that target specific oncogenic proteins, utilizing a proprietary library of over 10,000 compounds and advanced screening methods. The company addresses the challenge of targeting previously undruggable proteins involved in cancer progression, aiming to enhance treatment efficacy and improve patient outcomes.

This startup develops precision diagnosis software that predicts molecular pathology values from MRI images. The software analyzes MRI scans to assess the effects and side effects of specific treatment drugs, enabling healthcare providers to determine drug suitability for patients with degenerative brain diseases.

This company offers an AI-powered platform for chemical synthesis, automating reaction path planning and execution to accelerate drug discovery. Their technology helps pharmaceutical companies shorten the chemical synthesis phase of drug development through automated experimentation and analysis.

BathGenBio utilizes artificial intelligence to analyze extensive biobank data, including genomic and clinical information, to identify novel biomarkers and optimize drug discovery processes. The platform addresses the challenges of precision medicine by enhancing target discovery, drug response prediction, and drug repurposing for medical institutions and biotechnology companies.

CK Regeon Inc. develops First-In-Class drugs with a clear mechanism of action (MOA) to treat various diseases, enhancing the quality of human life. The company's focus on precise drug development addresses the need for effective therapies in the biotechnology sector.

Description: Quanmol Tech develops a molecular quantification platform that utilizes advanced analytical techniques to enhance chemical product design. This technology enables precise measurement of molecular properties, facilitating the development of more effective and tailored chemical solutions. Web Content:

The startup operates a research and development platform focused on synthesizing low molecular weight compounds for new drug candidates. By streamlining the drug development process, the company enables researchers to accelerate timelines and improve the conditions for commercializing new pharmaceuticals.

The startup utilizes a systems biology approach to analyze omics data for drug repositioning, enabling the identification of new therapeutic uses for existing pharmaceuticals. This method addresses the challenge of lengthy and costly drug discovery processes by leveraging already commercialized drugs to find unexpected treatments for various diseases.

The startup has developed an AI-based drug discovery engine that analyzes patient genetic data and disease mutations to identify the most effective medication for individual conditions. By comparing molecular and clinical profiles, the platform enhances treatment precision, ultimately improving patient outcomes and quality of life.

NUMENOS utilizes AI-driven Foundation Models to enhance drug development by integrating and analyzing real-world data and clinical trial data, enabling biomarker-driven target discovery and patient stratification. This approach significantly reduces trial sizes by 50-70% and increases trial significance by an average of 10 times, addressing the inefficiencies of traditional drug development methods.

The startup offers a drug discovery management platform that integrates IT services for clinical trials, enabling healthcare companies to efficiently manage image data, data warehousing, and medical monitoring throughout the drug development process. This platform addresses the challenges of data organization and accessibility for both ongoing and completed clinical trials, enhancing the overall management of the drug discovery pipeline.

AIGEN Sciences is an AI-driven platform that utilizes machine learning algorithms to accelerate drug discovery and development processes. The platform addresses the lengthy and costly nature of traditional drug research by providing data-driven insights that enhance target identification and compound optimization.

Biobab AiBIO utilizes artificial intelligence and Cryo-EM technology to develop novel pharmaceuticals, focusing on enhancing drug discovery efficiency. The company addresses the challenge of slow and costly drug development processes by streamlining molecular analysis and candidate selection.

RadaHaim has developed a high-throughput organoid assay system that enables the automated production of organoids tailored to specific tumor and cell types for drug screening. This technology addresses the inefficiencies in the drug discovery process by providing accurate disease models that bridge the gap between basic research and clinical trials.

MindRank utilizes a proprietary AI platform to accelerate small molecule drug discovery, focusing on hard-to-drug molecular targets for conditions like obesity and type 2 diabetes. Their lead candidate, MDR-001, achieved US IND approval in just 19 months, demonstrating the platform's efficiency in delivering potent and novel therapeutics.

The startup provides an AI-driven spatial analysis platform that utilizes machine learning algorithms to identify and characterize cancerous tumors. This technology enhances the pharmaceutical sector's ability to develop targeted therapies by delivering precise biological insights into complex diseases.

StoneWise develops the StoneMIND® platform, which utilizes AI to streamline the extraction and optimization of molecular data for drug discovery. This technology addresses the inefficiencies in traditional drug development processes by enabling rapid identification and design of drug candidates from extensive research data.